Quantum Cyber N.V. Completes $6M Private Placement, Undergoes Change of Control and Board Overhaul

summarizeSummary

Quantum Cyber N.V. (formerly Mainz Biomed N.V.) completed a $6 million private placement with David E. Lazar, leading to a change of control, a new board, and a massive increase in authorized shares, addressing going concern issues at the cost of extreme shareholder dilution.

check_boxKey Events

• $6 Million Private Placement Completed

  The company finalized a $6 million private placement of convertible preferred shares with David E. Lazar, with the second tranche closing on April 22, 2026, providing critical capital.

• Change of Control

  David E. Lazar became the controlling shareholder, holding over 95% of the company's voting rights on a fully-diluted basis as a result of the financing.

• Extreme Dilution Authorized

  The preferred shares are convertible into up to 477 million ordinary shares, representing a substantial increase over current outstanding shares and enabling significant future dilution for existing shareholders.

• Corporate Rebranding and Governance Overhaul

  The company changed its name from Mainz Biomed N.V. to Quantum Cyber N.V., saw the resignation of four directors and its Co-CEO, and appointed two new directors, significantly restructuring its board and management.

auto_awesomeAnalysis

This 8-K details a comprehensive corporate transformation for Quantum Cyber N.V., formerly Mainz Biomed N.V. The completion of a $6 million private placement with David E. Lazar, while providing critical capital to a company previously facing "going concern" doubts, comes at an extremely high cost to existing shareholders due to the massive potential dilution. David Lazar's acquisition of over 95% of voting rights signifies a complete change of control, which is further reflected in the significant overhaul of the board of directors and the resignation of the Co-CEO. The company's rebranding and the dramatic increase in authorized shares underscore a new strategic direction and the potential for further substantial equity issuance. Investors should recognize this as a recapitalization that effectively transfers control and a large portion of equity value to the new investor, fundamentally altering the investment thesis.